ClinicalTrials.gg
RecruitingNCT07697495Updated Jul 13, 2026

Scapulothoracic Stabilization and Postural Training in Upper Extremity Lymphedema

An interventional study of Complex Decongestive Therapy and Scapulothoracic Stabilization and Postural Training in Secondary Lymphedema, sponsored by Toros University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Toros University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Mar 2026, registered Jul 2026).
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Lymphedema with a site in Turkey — 12 open to participants now, 16 under way, none of them phase 3. Lymphedema · Turkey.

Planned enrollment
10th of 45
60 · median 40
Started
2026
with 8 others
No phase
44 of 65
11 open now
Primary completion
2027-03
later than 12 of 15 live
Registered
62nd of 65
by date

Among the 65 studies in Lymphedema with a site in Turkey, this one is the 10th largest by planned enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2026, is one of 44 with no phase, reaches primary completion later than 12 of the 15 other live ones, and was the 62nd registered.

Lymphedema

529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.

Browse Lymphedema studies →

Open to participants now

12 of the 65 studies in Lymphedema with a site in Turkey are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Lymphedema with a site in Turkey, or all of them as a file.
02

Study summary

This single-center randomized controlled trial aims to investigate the effects of adding scapulothoracic stabilization and postural training to standard lymphedema care in women with secondary upper extremity lymphedema following breast cancer surgery. Participants will be randomly assigned to receive either standard lymphedema care alone or standard care combined with scapulothoracic stabilization and postural training. Outcomes including scapular muscle strength, posture, upper extremity function, limb volume, and neck awareness will be assessed at baseline, immediately after treatment, and at a 2-month follow-up. The findings are expected to provide evidence regarding the effectiveness of incorporating targeted stabilization and postural exercises into conventional lymphedema rehabilitation.

Read the detailed description

Secondary upper extremity lymphedema is a common complication following breast cancer treatment and is characterized by chronic swelling, pain, reduced muscle strength, impaired upper extremity function, and postural alterations. These impairments may negatively affect daily activities, body perception, and quality of life. Although Complex Decongestive Therapy (CDT) is considered the gold standard for lymphedema management, conventional treatment primarily focuses on edema reduction and does not specifically address scapular stability, postural alignment, or neuromuscular control.

Altered scapulothoracic biomechanics and postural dysfunction are frequently observed in individuals with breast cancer-related lymphedema. These impairments may contribute to shoulder dysfunction, muscle weakness, compensatory movement patterns, and persistent functional limitations. Scapulothoracic stabilization exercises aim to restore scapular muscle balance and improve dynamic shoulder stability, whereas postural training promotes optimal alignment and body awareness. The combined application of these interventions may enhance functional recovery beyond the effects of standard CDT alone; however, evidence from randomized controlled trials remains limited.

This single-center, prospective, randomized controlled trial aims to evaluate the effectiveness of adding scapulothoracic stabilization and postural training to standard lymphedema care in women with secondary upper extremity lymphedema following breast cancer surgery. Participants will be randomly allocated to either a control group receiving standard lymphedema care or an intervention group receiving standard care plus scapulothoracic stabilization and postural training. Randomization will be performed using a computer-generated allocation sequence, and all outcome assessments will be conducted by a blinded assessor.

Outcome measures will be collected at baseline, immediately after completion of treatment, and at a 2-month follow-up. Primary and secondary outcomes will include scapular muscle strength measured with a handheld dynamometer (MicroFET2), postural alignment assessed using the PostureScreen application, upper extremity function evaluated with the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire, limb volume calculated from serial circumference measurements, and neck awareness assessed using the Fremantle Neck Awareness Questionnaire (FreNAQ). The findings of this study are expected to provide evidence regarding the clinical benefits of incorporating targeted scapulothoracic stabilization and postural training into conventional lymphedema rehabilitation and may contribute to the development of more comprehensive rehabilitation protocols for breast cancer survivors.

03

Conditions studied

  • Secondary Lymphedema

Browse trials for

Keywords

  • Upper Extremity Lymphedema
  • Scapulothoracic Stabilization
  • Postural Training
  • Muscle Strength
  • Posture
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 to 65 years.
  • Diagnosed with secondary upper extremity lymphedema following breast cancer surgery (mastectomy).
  • Willing to participate in the study.
  • Able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Active infection (e.g., cellulitis or lymphangitis).
  • Advanced shoulder or cervical pathology.
  • Neurological disorders affecting upper extremity function.
  • disease.
  • Receiving active chemotherapy.
  • Participation in another intensive lymphedema rehabilitation program within the previous 3 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Scapulothoracic Stabilization

    Participants assigned to the experimental group will receive standard Complex Decongestive Therapy (CDT), including manual lymphatic drainage, compression therapy, skin care, and therapeutic exercises, together with a structured scapulothoracic stabilization and postural training program. The additional exercise program is designed to improve scapular muscle function, postural alignment, and upper extremity function. Assessments will be performed at baseline, immediately after treatment, and at a 2-month follow-up.

    Procedure: Complex Decongestive Therapy · Behavioral: Scapulothoracic Stabilization and Postural Training

  • Active comparator
    Control

    Participants assigned to the control group will receive standard Complex Decongestive Therapy (CDT), including manual lymphatic drainage, compression therapy, skin care, and therapeutic exercises according to routine clinical practice. Outcome assessments will be performed at baseline, immediately after treatment, and at a 2-month follow-up.

    Procedure: Complex Decongestive Therapy

Interventions

  • ProcedureComplex Decongestive Therapy

    Standard Complex Decongestive Therapy consisting of manual lymphatic drainage, compression therapy, skin care, and therapeutic exercises. Treatment will be delivered according to established clinical guidelines and routine lymphedema rehabilitation protocols.

  • BehavioralScapulothoracic Stabilization and Postural Training

    A supervised exercise program consisting of scapulothoracic stabilization exercises and postural training designed to improve scapular muscle strength, postural alignment, and upper extremity function. The program will be provided in addition to standard Complex Decongestive Therapy throughout the treatment period.

06

What researchers measure

Primary outcomes

  1. Change in Upper Extremity Function

    Upper extremity function will be assessed using the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The DASH is a validated 30-item patient-reported outcome measure evaluating symptoms and functional limitations of the upper extremity. Scores range from 0 to 100, with higher scores indicating greater disability.

    Time frame: Baseline, immediately after completion of treatment, and 2 months after treatment

  2. Change in Head Anterior Translation

    Head anterior translation will be assessed using the PostureScreen mobile application.

    Time frame: Baseline, immediately after completion of treatment, and 2 months after treatment

  3. Change in Shoulder Height Asymmetry

    Shoulder height asymmetry will be assessed using the PostureScreen mobile application.

    Time frame: Baseline, immediately after completion of treatment, and 2 months after treatment.

  4. Change in Shoulder Anterior Translation

    Shoulder anterior translation will be assessed using the PostureScreen mobile application.

    Time frame: Baseline, immediately after completion of treatment, and 2 months after treatment.

Secondary outcomes

  1. Change in Scapular Muscle Strength

    Scapular muscle strength (upper, middle, and lower trapezius muscles) will be measured using a handheld dynamometer (MicroFET2) with the isometric make-test method.

    Time frame: Baseline, immediately after completion of treatment, and 2 months after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 175 non-industry interventional studies with no phase under Lymphedema, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 68. This study's planned 12 months is below that.

Counting every sponsor, half of 197 studies reached it within 25 months; a quarter within 11 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 13, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07697495
Lead sponsor
Toros University
Responsible party
Idil Esin Unlu (Asst. Prof., Toros University) — Principal investigator
First posted
Jul 13, 2026
Start date
Mar 1, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jul 13, 2026

Study contacts

İdil Esin Ünlü, Assist. Prof. Dr.
Contact
idil.unlu@toros.edu.tr
+90 506 515 66 22

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion